Article List

1. Alcohol and hepatocarcinogenesis	Page:736—741
2. Nonalcoholic fatty liver disease and alcohol-related liver disease: From clinical aspects to pathophysiological insights	Page:728—735
3. Long non-coding RNAs in liver diseases: Focusing on nonalcoholic fatty liver disease, alcohol-related liver disease, and cholestatic liver disease	Page:705—714
4. Oxidative stress and glutamate excretion in alcoholic steatosis: Metabolic synapse between hepatocyte and stellate cell	Page:697—704
5. Roles of the complement system in alcohol-induced liver disease	Page:677—685
6. Liver-lung axes in alcohol-related liver disease	Page:670—676
7. Global and regional impacts of alcohol use on public health: Emphasis on alcohol policies	Page:652—661
8. Predictors of steroid non-response and new approaches in severe alcoholic hepatitis	Page:639—651
9. Inter-professional and inter-departmental alcoholism rehabilitation program	Page:626—632
10. Autophagy and liver cancer	Page:606—617
11. The 14th International Symposium on Alcoholic Liver and Pancreatic Diseases and Cirrhosis (ISALPDC)	Page:584—585
12. Clinical outcomes of coronavirus disease 2019 in patients with pre-existing liver diseases: A multicenter study in South Korea	Page:562—576
13. Acute-on-chronic liver failure: A predictor of poor prognosis in patients with variceal bleeding or a risk factor for variceal bleeding?	Page:487—488
14. Targeting epithelial-mesenchymal transition pathway in hepatocellular carcinoma	Page:484—486
15. Sarcopenia and blood myokine levels as prognostic biomarkers in patients with liver cirrhosis or hepatocellular carcinoma	Page:476—479
16. Managing liver cirrhotic complications: Overview of esophageal and gastric varices	Page:444—460
17. Hepatic Hippo signaling inhibits development of hepatocellular carcinoma	Page:742—750
18. Emerging medical therapies for severe alcoholic hepatitis	Page:686—696
19. The effect of moderate alcohol drinking in nonalcoholic fatty liver disease	Page:662—669
20. Lean non-alcoholic fatty liver disease: Is there a place for novel antidiabetics in the therapeutic management of this underappreciated “enemy”?	Page:582—583
21. More evidence that direct acting antiviral therapy is safe and effective in cirrhosis and chronic kidney disease including peritoneal dialysis	Page:489—491
22. Endoplasmic reticulum stress and autophagy dysregulation in alcoholic and non-alcoholic liver diseases	Page:715—727
23. The lymphatic system in alcohol-associated liver disease	Page:633—638
24. Programmed cell death in alcohol-associated liver disease	Page:618—625
25. Long-term prognosis and management of hepatocellular carcinoma after curative treatment	Page:480—483
26. Obesity and binge alcohol intake are deadly combination to induce steatohepatitis: A model of high-fat diet and binge ethanol intake	Page:586—594
27. Phosphoinositide 3-kinase inhibitors are effective therapeutic drugs for the treatment of hepatocellular carcinoma?	Page:577—578
28. Acute-on-chronic liver failure as a major predictive factor for mortality in patients with variceal bleeding	Page:540—553
29. From intestinal dysbiosis to alcohol-associated liver disease	Page:595—605
30. Substantial risk of recurrence even after 5 recurrence-free years in early-stage hepatocellular carcinoma patients	Page:516—528
31. Precision medicine in nonalcoholic fatty liver disease: New therapeutic insights from genetics and systems biology	Page:461—475
32. Use of glecaprevir/pibrentasvir in patients with chronic hepatitis C virus infection and severe renal impairment	Page:554—561
33. Comparison of clinical practice guidelines for the management of chronic hepatitis B: When to start, when to change, and when to stop	Page:411—429
34. Inhibition of PI3K/Akt signaling suppresses epithelial-to-mesenchymal transition in hepatocellular carcinoma through the Snail/GSK-3/beta-catenin pathway	Page:529—539
35. Beneficial effect of anti-diabetic drugs for nonalcoholic fatty liver disease	Page:430—443
36. Evidence-based clinical advice for nutrition and dietary weight loss strategies for the management of NAFLD and NASH	Page:383—400
37. Stereotactic body radiation therapy for small (≤5 cm) hepatocellular carcinoma not amenable to curative treatment: Results of a single-arm, phase II clinical trial	Page:506—515
38. The association of the serum levels of myostatin, follistatin, and interleukin-6 with sarcopenia, and their impacts on survival in patients with hepatocellular carcinoma	Page:492—505
39. Liver graft from donation after circulatory death donor: Real practice to improve graft viability	Page:401—410

Volume: 26 Issue: 4